CSIMarket
 


Concert Pharmaceuticals Inc   (CNCE)
Other Ticker:  
 

Concert Pharmaceuticals Inc 's Quick Ratio

CNCE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth




CNCE Quick Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 44.74 % 86.39 % 81.65 % 58.38 % 63.13 %
Y / Y Cash & cash equivalent Change -9.75 % 12.21 % -35.22 % 80.75 % 189.98 %
Quick Ratio MRQ 5.51 8.67 4 8.88 8.84
Overall Ranking # # # # #
Seq. Current Liabilities Change 7.67 % 7.15 % -6.44 % 34.1 % 38.65 %
Seq. Cash & cash equivalent Change -31.57 % 132.46 % -57.89 % 34.72 % -14.92 %



Quick Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Quick Ratio fell to 5.51 above Concert Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry Concert Pharmaceuticals Inc booked the highest Quick Ratio than Concert Pharmaceuticals Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Quick Ratio?
What are CNCE Segments?
See Quick Ratio CNCE on the trailing twelve month basis
Quick Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Quick Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Concert Pharmaceuticals Inc 's Current Liabilities $ 17 Millions Visit CNCE's Balance sheet
Concert Pharmaceuticals Inc 's Cash & cash equivalent $ 96 Millions Visit CNCE's Balance sheet
Source of CNCE's Sales Visit CNCE's Sales by Geography


Cumulative Concert Pharmaceuticals Inc 's Quick Ratio

CNCE's Quick Ratio for the trailling 12 Months

CNCE Quick Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 44.74 % 86.39 % 81.65 % 58.38 % 63.13 %
Y / Y Cash & cash equivalent TTM Growth -9.75 % 12.21 % -35.22 % 80.75 % 189.98 %
Quick Ratio TTM 6.78 7.57 8.37 10.36 10.29
Total Ranking TTM # 189 # 124 # 529 # 266 # 453
Seq. Current Liabilities TTM Growth 7.67 % 7.15 % -6.44 % 34.1 % 38.65 %
Seq. Cash & cash equivalent TTM Growth -31.57 % 132.46 % -57.89 % 34.72 % -14.92 %


TTM Quick Ratio Comment
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $17.40 millions, average cumulative Quick Ratio decreased to 6.78 below the Concert Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 82 other companies have achieved higher Quick Ratio than Concert Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. 189.

Explain Quick Ratio?
What are CNCE Segments?
See Quick Ratio CNCE on the trailing twelve month basis

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 83
Healthcare Sector # 134
Within the Market # 189


TTM Quick Ratio Statistics
High Average Low
23.88 11.53 3.21
(Dec 31 2017)   (Jun 30 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Fulcrum Therapeutics Inc   15.09 $ 221.789  Millions$ 14.699  Millions
Crinetics Pharmaceuticals Inc   15.00 $ 368.362  Millions$ 24.556  Millions
Nkarta Inc   14.85 $ 392.356  Millions$ 26.425  Millions
Akero Therapeutics Inc   14.82 $ 374.003  Millions$ 25.243  Millions
Pds Biotechnology Corp  14.80 $ 71.642  Millions$ 4.841  Millions
Oric Pharmaceuticals Inc   14.58 $ 193.659  Millions$ 13.284  Millions
Cytokinetics Incorporated  14.36 $ 867.664  Millions$ 60.440  Millions
Cryoport inc   14.31 $ 530.451  Millions$ 37.076  Millions
Lianbio  14.15 $ 311.728  Millions$ 22.027  Millions
Catalyst Biosciences Inc   14.05 $ 23.090  Millions$ 1.644  Millions
Sage Therapeutics Inc   13.98 $ 1,393.639  Millions$ 99.687  Millions
Pliant Therapeutics Inc   13.77 $ 360.241  Millions$ 26.161  Millions
Sensei Biotherapeutics Inc   13.73 $ 116.558  Millions$ 8.492  Millions
Rani Therapeutics Holdings Inc   13.66 $ 98.171  Millions$ 7.186  Millions
Lumos Pharma Inc   13.44 $ 73.666  Millions$ 5.483  Millions
Annexon Inc   13.33 $ 269.519  Millions$ 20.220  Millions
Larimar Therapeutics Inc   13.24 $ 124.699  Millions$ 9.420  Millions
Liquidia Corporation  13.18 $ 98.320  Millions$ 7.460  Millions
Xenetic Biosciences Inc   13.18 $ 13.848  Millions$ 1.051  Millions
Aclaris Therapeutics Inc   13.04 $ 248.062  Millions$ 19.023  Millions
Iveric Bio Inc   13.04 $ 320.535  Millions$ 24.588  Millions
Erasca Inc   12.86 $ 355.928  Millions$ 27.679  Millions
Arcutis Biotherapeutics Inc   12.86 $ 476.963  Millions$ 37.102  Millions
Kronos Bio Inc   12.85 $ 258.255  Millions$ 20.105  Millions
Verrica Pharmaceuticals Inc   12.82 $ 39.454  Millions$ 3.078  Millions
Lyell Immunopharma Inc   12.65 $ 648.132  Millions$ 51.217  Millions
Pepgen Inc   12.62 $ 195.783  Millions$ 15.519  Millions
Graybug Vision Inc   12.61 $ 43.627  Millions$ 3.460  Millions
Histogen Inc   12.41 $ 14.552  Millions$ 1.173  Millions
Reneo Pharmaceuticals Inc   12.28 $ 116.080  Millions$ 9.450  Millions

Date modified: 2022-11-08T16:42:48+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

APHE's Profile

Stock Price

APHE's Financials

Business Description

Fundamentals

Charts & Quotes

APHE's News

Suppliers

APHE's Competitors

Customers & Markets

Economic Indicators

APHE's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Š 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071